Cramer: Avoid This Drug Stock
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva agrees to buy Allergan's generics distribution unit
Pharma giant Teva looks to steady ship with new CEO in coming weeks | The Times of Israel
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
EU antitrust authorities launch probe of Teva over Copaxone drug | The Times of Israel
Generic-drug maker Teva steals market share from Big Pharma - Aug. 5, 2009
Generics distributor Anda, Inc. has a new owner: Teva Pharma
Silver Spring-based United Therapeutics settles patent dispute over Remodulin generic with Teva Pharmaceuticals - Washington Business Journal
Teva Pharmaceuticals to lay off 14,000 employees worldwide, 1,750 in Israel - The Jerusalem Post
Teva Pharmaceutical Industries Ltd. | BioWorld
Teva seeks blockbuster drug to succeed Copaxone - Globes
Teva Pharmaceuticals considers laying-off 10,000 workers - The Jerusalem Post
Why Teva Pharmaceutical Is Substantially More (NYSE:TEVA) | Seeking Alpha
FDA Approves Generic Version Of Teva's Blockbuster Drug - Drug Discovery and Development
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva Pharmaceutical Stock Could Double | Barron's
Teva to cut 14,000 jobs | Business | Chemistry World
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva's Blockbuster Drug Takes Another Generic Blow | Ctech
A determined FDA takes down Teva's blockbuster | Evaluate
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Roche's Ocrevus achieves blockbuster status - Pharmaceutical Technology
Teva Pharmaceutical to ax 14,000 workers worldwide - CBS News
Teva buys Allergan: 3 reasons why it's a blockbuster deal | Fortune
